Lucis

Lucis, based in Paris, France, specializes in personalized health assessment services that empower individuals to proactively manage their long-term wellness through comprehensive health insights and data-driven strategies. Lucis provides health assessment services designed to enhance individuals' wellness journey. Founded in 2024 in Paris, France, the company has successfully completed one deal as of December 16, 2025. The latest funding round was a Seed round, where Lucis raised USD 8.

5 mn, led by General Catalyst Partners, with participation from Circle & Co, Kima Ventures, Motier Ventures, North South Ventures, and Y Combinator. Lucis offers a comprehensive health assessment service that includes biannual health checks covering over 100 biomarkers related to cardiovascular function, metabolic status, and hormone levels. Collaborating with certified laboratories in Europe, including locations in France, the UK, Ireland, and Portugal, Lucis provides a personalized dashboard that simplifies health results and offers actionable insights tailored to users. Their target clientele comprises health-conscious individuals aged 18 and older seeking to improve their health through informed decisions.

Lucis operates on a subscription-based revenue model, where users pay for membership that includes two comprehensive health assessments annually and continuous access to health insights. Revenue is generated from membership fees, with options for additional tests beyond the standard offerings. The service is designed to ensure confidentiality, with user data shared strictly with the Lucis medical team upon explicit consent. In December 2025, Lucis raised USD 8.

5 mn in Seed funding, which will be utilized to expand operations across Europe, enhance partnerships with laboratories and healthcare providers, and improve its health tracking platform. The company is focused on increasing its market footprint and is actively developing new products to enhance its offerings, aiming for timely rollouts in the upcoming period.